| __timestamp | Bio-Techne Corporation | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 60716000 | 26684000 |
| Thursday, January 1, 2015 | 119401000 | 29829000 |
| Friday, January 1, 2016 | 140879000 | 39578000 |
| Sunday, January 1, 2017 | 199243000 | 43277000 |
| Monday, January 1, 2018 | 240636000 | 48645000 |
| Tuesday, January 1, 2019 | 264359000 | 52934000 |
| Wednesday, January 1, 2020 | 260583000 | 61349000 |
| Friday, January 1, 2021 | 324951000 | 127125000 |
| Saturday, January 1, 2022 | 372766000 | 136106000 |
| Sunday, January 1, 2023 | 378378000 | 133175999 |
| Monday, January 1, 2024 | 396826000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Bio-Techne Corporation and HUTCHMED (China) Limited, two prominent players, offer a fascinating study in contrasts. Over the past decade, Bio-Techne has seen its SG&A expenses grow by over 550%, peaking at nearly $400 million in 2024. In contrast, HUTCHMED's expenses have increased by approximately 400%, reaching a high of $136 million in 2022. This disparity highlights Bio-Techne's aggressive expansion strategy, while HUTCHMED appears more conservative. Notably, HUTCHMED's data for 2024 is missing, suggesting potential changes in reporting or strategy. As investors and analysts look to the future, understanding these trends is key to predicting which company will better manage its costs and, ultimately, its market position.
Novartis AG or Bio-Techne Corporation: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Bio-Techne Corporation
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Bio-Techne Corporation vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Bausch Health Companies Inc.
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Taro Pharmaceutical Industries Ltd.
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Evotec SE
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs HUTCHMED (China) Limited Trends and Insights
Axsome Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Amicus Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
HUTCHMED (China) Limited vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends